Zildaglip M 500mg/50mg Tablet is a combination oral antidiabetic medication containing Metformin 500mg and Vildagliptin 50mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner, contributing to improved postprandial and fasting blood glucose levels. The combined action of these agents provides complementary mechanisms to achieve better glycemic control compared to monotherapy. Zildaglip M is typically prescribed as an adjunct to diet and exercise to improve glycemic parameters in adult patients inadequately controlled on either agent alone. It is important to monitor renal function prior to and during treatment due to Metformin’s renal clearance and risk of lactic acidosis in patients with impaired kidney function. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while Vildagliptin is generally well tolerated with a low risk of hypoglycemia. Dose adjustments and contraindications should be carefully considered by healthcare professionals.